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Generation of human induced pluripotent stem cells (hiPSCs) by the
expression of specific transcription factors depends on successful
epigenetic reprogramming to a pluripotent state. Although hiPSCs
and human embryonic stem cells (hESCs) display a similar epigenome,
recent reports demonstrated the persistence of specific epigenetic
marks from the somatic cell type of origin and aberrant methylation
patterns in hiPSCs. However, it remains unknownwhether the use of
different somatic cell sources, encompassing variable levels of se-
lection pressure during reprogramming, influences the level of
epigenetic aberrations in hiPSCs. In this work, we characterized the
epigenomic integrity of 17 hiPSC lines derived from six different cell
types with varied reprogramming efficiencies. We demonstrate that
epigenetic aberrations are a general feature of the hiPSC state and
are independent of the somatic cell source. Interestingly, we observe
that the reprogramming efficiency of somatic cell lines inversely
correlates with the amount ofmethylation change needed to acquire
pluripotency. Additionally, we determine that both shared and line-
specific epigenetic aberrations in hiPSCs can directly translate into
changes in gene expression in both the pluripotent and differenti-
ated states. Significantly, our analysis of different hiPSC lines from
multiple cell types of origin allow us to identify a reprogramming-
specific epigenetic signature comprised of nine aberrantly methyl-
ated genes that is able to segregate hESC and hiPSC lines regardless
of the somatic cell source or differentiation state.
Induction of pluripotency in human somatic cells is an in-efficient process that can be achieved by the expression of
defined transcription factors (1–5). This reprogramming process
involves global epigenetic remodeling and overcoming similar
roadblocks present during cell transformation, which might af-
fect genomic and epigenomic integrity (6). In fact, several recent
reports have shown that human induced pluripotent stem cells
(hiPSCs) contain genetic and epigenetic aberrations throughout
their genome compared with their parental somatic cell pop-
ulations or to human embryonic stem cells (hESCs) (7–12). For
example, the analysis of whole-genome DNA methylation pro-
files at single-nucleotide resolution in hiPSCs, their somatic cells
of origin, and hESCs revealed the presence of more than 1,000
differentially methylated regions (DMRs) between hiPSCs and
hESCs (11). Moreover, this analysis, and many others, demon-
strated both the persistence of specific epigenetic marks from the
somatic cell of origin (residual methylation) and the acquisition
of unique methylation patterns in mouse iPSCs (miPSCs) and
hiPSCs (11, 13–21). Interestingly, hiPSC lines also show in-
complete reprogramming of non-CG methylation in regions
proximal to telomeres and centromeres (11). Altogether, these
epigenetic aberrations might explain some of the observed
transcriptional variation between hESC and hiPSC lines (22–24).
In one of the most comprehensive reports to date, Bock et al.
(23) characterized a panel of 20 hESC and 12 hiPSC lines to
demonstrate that despite their global similarity, a number of genes
in each pluripotent cell line deviated from the normal expected
variation compared with the DNA methylation and gene expres-
sion levels observed in the other pluripotent cell lines. In-
terestingly, they reported that no apparent epigenetic deviation
was unique to all hiPSC lines (23). Altogether, these findings
demonstrate that hiPSCs contain epigenetic aberrations. How-
ever, a majority of these reports predominantly used fibroblast-
derived hiPSC lines and, thus, it remains unknown whether the
use of alternative somatic cell types with variable levels of se-
lection pressure for reprogramming might result in hiPSC lines
containing fewer (or perhaps none) of these epigenetic alter-
ations. Furthermore, although it has been shown that aberrantly
methylated CpG sites are transmitted to differentiated cells (11), it
remains unclear whether these epigenetic aberrancies result in
transcriptional variation after differentiation.
In this work, we characterize at single nucleotide resolution the
methylation profile of 17 hiPSC lines derived from six different so-
matic cell types with varied reprogramming efficiencies. Our results
show that, independent of the somatic cell source used for reprog-
ramming, all hiPSC lines analyzed contain abnormal epigenetic pat-
terns. We determine that a majority of these aberrantly methylated
CpG sites are transmitted to differentiated cells and can be associ-
ated with changes in gene expression after differentiation. Impor-
tantly, we identify a reprogramming-associated epigenetic signature
comprised of nine aberrantly methylated genes that can segregate
hESC and hiPSC lines both in the pluripotent state and after dif-
ferentiation. These observations will contribute to a deeper under-
standing of the reprogramming process and underscore the need for
a rigorous evaluation of the epigenetic integrity of hiPSC lines.
Results
Reprogramming Efficiency Inversely Correlates with the Percentage
of Epigenetic Modifications Observed After Reprogramming. To gain
insight into the epigenetic integrity of hiPSCs, we performed
targeted bisulfite sequencing with padlock probes (25, 26) to
analyze the methylomes of 17 hiPSC lines, their 6 somatic cell
Author contributions: S.R., D.D., A. Gore, K.Z., and J.C.I.B. designed research; S.R., D.D.,
A. Gore, A.D.P., N.M., N.P., H.-L.F., A. Giorgetti, J.B., E.M.B., N.G.K., and M.M. performed
research; H.Z. and H.R.S. contributed new reagents/analytic tools; S.K. analyzed data; and
S.R., D.D., A. Gore, A.D.P., K.Z., and J.C.I.B. wrote the paper.
The authors declare no conflict of interest.
This article is a PNAS Direct Submission. K.P. is a guest editor invited by the Editorial
Board.
The array as well as the methylation data reported in this paper have been deposited in
the Gene Expression Omnibus (GEO database), www.ncbi.nlm.nih.gov/geo (accession nos.
GSE39210 and GSE40372).
1S.R. and D.D. contributed equally to this work.
2To whom correspondence may be addressed. E-mail: belmonte@salk.edu or kzhang@
bioeng.ucsd.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1202352109/-/DCSupplemental.
16196–16201 | PNAS | October 2, 2012 | vol. 109 | no. 40 www.pnas.org/cgi/doi/10.1073/pnas.1202352109
types of origin, and 7 hESC lines (SI Text, Fig. S1, and Table S1).
We designed and synthesized a set of 330,000 synthetic probes
targeting ∼140,000 genomic regions known to be differentially
methylated across different cell types (12, 27, 28) and additional
functional regions. We determined the absolute methylation
levels for an average of ∼529,000 CpG sites per sample (Table S1).
Although only ∼1% of the human genome was covered by this
assay, these preselected CpG sites were more than twice as
informative as typical sites in CpG islands characterized by
using lower resolution sequencing or in previously used bisulfite
sequencing methods (Table S2). Unbiased hierarchical clustering
of global methylation levels demonstrated a clear segregation of
somatic cells and pluripotent cells (Fig. 1A). We also observed
that hiPSC lines originating from the same somatic cell type ten-
ded to cluster together in subgroups (Fig. 1 A and B), which, as
reported (11, 13–21), supports the existence of residual methyla-
tion from somatic cells of origin in hiPSCs.
We analyzed the number of differentially methylated CpG sites
(DMSs) in each hiPSC line by comparing each cell line to its direct
somatic cell source of origin (Table S2). We observed that between
23% and 37% of CpG sites analyzed underwent a change in meth-
ylation state, with mesenchymal stem cells (MSCs) and fibroblasts
requiring the most dramatic epigenetic change following reprog-
ramming and neural stem cells (NSCs) requiring the least (Table
S2). Interestingly, the percentage of DMSs after reprogramming
correlated inversely with reprogramming efficiency, with cell
sources undergoing the fewest epigenetic modifications reprog-
ramming at higher efficiency (Fig. 1C). Moreover, we confirmed
previous findings (11) and determined that, independent of somatic
cell source, the global change in methylation observed after re-
programming is toward a more methylated state (Fig. S2A). Next,
we investigated whether different somatic cell sources shared a
core set of DMSs that might be essential to epigenetically repro-
gram to a pluripotent state. In fact, we observed that ∼5,700 DMSs
were shared among all hiPSC lines (Fig. S2B). Analysis of Gene
Ontology for genes that could potentially be regulated by these
DMSs revealed that genes with hypomethylatedDMSs appeared to
be enriched for cell signaling, protein refolding, cell metabolism,
and neuronal development, whereas genes with hypermethylated
DMSs appeared to be enriched for cell-cell adhesion and re-
ceptor behavior (Dataset S1).
hiPSC Lines Share a Core Set of Aberrantly Methylated Genes That
Segregate Them from hESCs. We compared the methylation state
at each CpG site in individual hiPSC lines to that of their pa-
rental source and seven hESC lines. Using an algorithm based on
the χ2 test with multiple testing corrections, we identified sites
where hiPSC lines carried a methylation pattern significantly
different from hESC lines (SI Materials and Methods). hiPSC
lines derived from the same somatic cell source carried similar,
although not identical, aberrant methylation patterns and clus-
tered together based on methylation level at aberrant sites (Fig.
2A). We categorized the aberrantly methylated CpG sites into
two categories: residual methylation, where the CpG site in
a hiPSC line retains the methylation level of its parental cell
instead of reaching the level observed in hESCs (Fig. 2B), and de
novo methylation, where the CpG site in a hiPSC line acquires
a methylation state found neither in its somatic source nor in
hESCs (Fig. 2B). We determined that the percentage of aberrant
CpG sites varied between 0.92% and 3.82% across the hiPSC
lines analyzed. Furthermore, the percentage of CpG sites that
showed residual methylation or de novo methylation varied be-
tween 0.32% and 1.60% and 0.57% and 2.98%, respectively
(Table 1). Although we did not find a direct correlation between
the amount of aberrant methylation and reprogramming efficiency
or somatic cell type, we noted that some cell types appeared to
possess lower aberrant methylation levels (e.g., astrocyte-derived
lines) compared with others (e.g., fibroblast-derived lines) (Table
1). We determined that most aberrantly methylated CpG sites
showing de novo methylation were characterized by excessive
methylation after reprogramming (Fig. 2C), whereas most aber-
Fig. 1. Identification and classification of the epigenetic changes occur-
ring during cell reprogramming. (A) Hierarchical clustering of the in-
dicated cell lines based on the methylation state of all characterized CpG
sites. HUVEC, human umbilical vein endothelial cell; K-MMTA, keratino-
cyte cell line; MSC, mesenchymal stem cell; NSC, neural stem cell; PGP1F,
HFF.XF, IMR90, fibroblasts lines. (B) Heatmap and ordered dendrogram for
all hiPSC lines based on the level of relative change observed at each
differentially methylated site compared with the values observed in each
respective somatic cell of origin. Pearson’s correlation values were used to
generate a single distance metric. (C ) Reprogramming efficiency of so-
matic cell lines estimated after hiPSCs generation by retroviral infection of
OCT4, SOX2, KLF4, and cMYC inversely correlates with the percentage of
differential methylation achieved in hiPSC lines. Note that amount of
epigenetic reorganization required appears to be a barrier to reprog-
ramming. R2, Pearson’s correlation value.








rantly methylated CpG sites associated with genes showing re-
sidual methylation were characterized by only partial methylation
occurring after reprogramming (Fig. 2D).
To gain insight into potential functional consequences of these
epigenetic aberrations, we linked each aberrant CpG site with
its closest gene (SI Materials and Methods) and used this subset of
genes for further analysis. Interestingly, we observed that a very
small number of genes contained aberrant methylation patterns
in nearly all hiPSC lines assayed in our study (16/17 hiPSC lines)
regardless of somatic cell source (Dataset S2). We hypothe-
sized that the nine genes (PTPRT, TMEM132C, TMEM132D,
TCERG1L, DPP6, FAM19A5, RBFOX1, CSMD1, and C22ORF34)
we identified might represent a core set of aberrantly methylated
genes that can systematically distinguish hiPSC and hESC lines.
Thus, we performed unbiased hierarchical clustering based on
the methylation status of CpG sites associated to this small
subset of genes in previously published independent methyla-
tion datasets. Specifically, we first examined a set of whole-ge-
nome bisulfite sequencing data performed in three hESC and
five hiPSC lines (11). We found that, similar to what we observed
for our dataset, the methylation level of CpG sites associated to
the nine genes was able to clearly segregate hESC and hiPSC
lines into two distinct groups (Fig. 2E). Additionally, we used
a recently published dataset that profiled the genome-wide DNA
methylation level for more than 450,000 CpG sites in 19 hESC
and 29 hiPSC lines (13) and observed that, despite the lower
Fig. 2. Pluripotent cells can be segregated based on the methylation/gene expression level of nine genes. (A) Heatmap and hierarchical clustering results of
the cell lines used in this study using methylation patterns at CpG sites containing aberrant methylation in at least one hiPSC line. Similar aberrant epigenetic
patterns were observed in hiPSCs derived from common somatic sources, and these lines accordingly tend to cluster together. (B) Graphical representation of
an example of residual methylation and de novo methylation located on chromosome 15 (ISLR2 gene). Each circle corresponds to an individual CpG site and
the level of methylation is represented in a colored pattern. In the example shown, NSChiPS2F retains the epigenetic pattern of its somatic progenitor (hNSC),
showing residual methylation. HUVhiPS4F1 takes on an epigenetic pattern not observed in its somatic progenitor or any of the other pluripotent lines,
showing a hiPSC line-specific de novo methylation. Methylation levels of the same CpG sites in hESC and hiPSC lines were included for comparison. (C and D)
Types of methylation errors leading to epigenetic aberrations. Most aberrantly methylated CpG sites associated to genes showing de novo methylation (C)
and residual methylation (D) in all hiPSC lines are characterized by overmethylation or partial methylation, respectively. (E) Heatmap and ordered den-
drogram for the hiPSC and hESC described lines (11) based on the level of relative change observed at CpG sites associated to our nine signature genes. Note
that hESC and hiPSC lines segregated in two different groups. (F) Hierarchical clustering of six hiPSC (ASThiPS4F2, 3, 4, and 5, HUVhiPS4F6, and FhiP4F2) and
six hESC (H1, H9, HUES2, HUES6, HUES8, and HUES9) lines based on the gene expression level analyzed by real-time PCR of the nine common aberrantly
methylated genes identified in hiPSC lines used in this study.
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resolution, a similar clustering analysis clearly segregated all but
two hiPSC lines from hESC lines (Fig. S3A).
Next, we investigated whether our core set of aberrantly
methylated genes showed differential gene expression in hiPSC
lines compared with hESC lines by performing real-time PCR
analysis on RNA obtained from six hiPSC lines and six hESC
lines (a description of the primers used in this study can be found
in Table S3). An unbiased hierarchical clustering of the real-time
PCR data results examining the gene expression of the nine
shared aberrantly methylated genes demonstrated a clear segre-
gation between hiPSC and hESC lines (Fig. 2F). Furthermore, to
determine the global relevance of these findings, we also per-
formed a similar unbiased hierarchical clustering by using pre-
viously reported independent datasets containing a variety of
hESC and hiPSC lines (a total of 12 datasets). Overall, when
examining the expression of these nine genes, we determined
that although clear outliers and different subgroups among
hiPSC lines were detected, a majority of the dataset clusters
showed separation between hiPSC and hESC lines (Fig. S3 B and
C and Dataset S2). These combined results suggest the existence
of shared epigenetic aberrancies associated to a small subset of
genes in hiPSC lines. The validation of these aberrancies by using
our data and data from independent laboratories strongly cor-
roborates the strength of our findings.
Aberrant Methylation at CpG Sites Is Transmitted During hiPSC
Differentiation, Resulting in Transcriptional Changes Compared with
Differentiated hESCs. To further test whether the aberrant meth-
ylation and gene expression levels observed in hiPSC lines were
maintained after loss of the pluripotent state, we differentiated
five hESC lines and five hiPSC lines toward two different germ
cell layers, endoderm and trophoectoderm, by using Activin-A
and BMP4, respectively. We then performed targeted bisulfite
sequencing to analyze the methylomes of the hESC and hiPSC
lines in their pluripotent and differentiated states (Table S1). In
addition, the gene expression levels of H9, HUVhiPS4F1 and
HUVhiPS4F3 were profiled in duplicate by using Affymetrix ST
1.0 microarrays. Between 0.3% and 1% of CpG sites were ab-
errantly methylated in the hiPSC lines with respect to hESC lines
(Dataset S3). We first investigated whether these epigenetic aber-
rations resulted in changes in gene expression in undifferentiated
cells. We observed that between 3% and 7% of genes linked
to these aberrantly methylated sites showed differential gene
expression in hiPSC lines compared with hESC lines (Fig. S4A
and Dataset S3). Additionally, we tested the expression of five
genes with line-specific epigenetic de novo methylation in
HUVhiPS4F1 and observed that these genes also showed dif-
ferential gene expression compared with other hiPSC or hESC
lines (Fig. S4B). Taken together, these results indicate that some
epigenetic aberrations are associated with changes in gene
expression levels.
We next analyzed the methylation status of the aberrant CpG
sites in both hiPSCs and hESCs after each differentiation pro-
tocol. The CpG sites were classified based on their postdif-
ferentiation methylation status into four categories (see Fig. 3
for a detailed description; Dataset S3). We observed that ∼20–
50% of the aberrantly methylated CpG sites detected in hiPSC
lines remained aberrant after differentiation into either of the
two separate cell lineages (Fig. 3A). Importantly, we observed that
a subset of genes associated with these CpG sites showing dif-
ferential gene expression level in undifferentiated hiPSCs com-
pared with hESCs still remain in that condition regardless of
differentiation protocol (Fig. 3B, Fig. S4C, and Dataset S3).
Finally, to further validate the potential of the identified hiPSC-
specific epigenetic signature described above, we clustered the
pluripotent cells and their differentiated progenies based on
both the methylation level and transcriptional abundance of the
nine signature genes (Fig. 3 C and D and Fig. S4D). Interestingly,
the samples segregated based on whether the progenitor line was
a hiPSC or hESC, and clustered by specific cell line but not by
differentiation protocol. Altogether, these data suggest that the
methylation and gene expression levels of the aberrantly meth-
ylated genes in hiPSC lines still segregate hESCs and hiPSCs
even after differentiation toward independent germ cell layers.
Discussion
In this work, we have used an expanded bisulfite padlock probe
set to interrogate the methylation level of targeted CpG sites
identified to carry differential methylation in various cell states
regardless of CpG density (12, 26–28). This unique approach
identified genes linked to individual aberrantly methylated CpG
sites that are not necessarily located in CpG-enriched genomic
regions. Our results show that epigenetic aberrations occur in
hiPSCs regardless of the somatic cell type of origin. We dem-
onstrated that aberrant epigenetic patterns in hiPSC lines in-
fluence gene expression and could explain functional diversity
Table 1. Summary of CpG sites containing residual methylation and de novo methylation in targeted regions
Cell line Testable sites % aberrant % memory % mutation
No. of genes potentially
affected by memory
No. of genes potentially
affected by mutation
ASThiPS4F4 434388 1.02 0.45 0.57 191 182
ASThiPS4F5 437266 0.92 0.35 0.58 211 186
ASThiPS4F1 404245 1.30 0.35 0.96 189 310
ASThiPS4F2 380656 1.16 0.41 0.75 171 243
ASThiPS4F3 343025 2.07 0.41 1.65 219 616
FhiPS4F7 340395 2.53 1.27 1.25 487 591
HUVhiPS4F1 374103 1.33 0.38 0.95 200 474
HUVhiPS4F3 392482 1.41 0.42 0.99 251 588
HUVhiPS4F6 433768 1.29 0.32 0.97 190 455
FhiPS4F2 354763 1.62 0.52 1.10 292 213
FhiPS4F5 296451 2.47 0.62 1.85 362 682
KhiPS4F8 396085 2.60 0.82 1.78 586 1040
KhiPS4FA 270126 2.41 0.46 1.95 288 831
MSChiPS4F4 437957 2.34 0.96 1.39 560 462
MSChiPS4F8 429575 2.85 1.60 1.25 896 552
NSChiPS2F 327308 3.82 0.84 2.98 538 1912
PGP1-iPS 437433 2.63 1.47 1.16 997 703
Aberrantly (residual and de novo) methylated CpG sites were classified as such when showing at least a 0.2 change in absolute methylation level and
considered to have methylation levels from different underlying distributions by the χ2 test (with Benjamini-Hochberg multiple testing correction, FDR =
0.01). Genes potentially affected by aberrantly methylated CpG sites were defined as described in SI Materials and Methods.








within hiPSC lines and between hiPSC and hESC lines (29–31).
In fact, we observed the existence of genes aberrantly methylated
and differentially expressed in hiPSC lines compared with hESCs
that still remained in that condition after differentiation regardless
of differentiation protocol.
The use of hiPSC lines derived from six different somatic cell
types enabled us to narrow down a precise core set of genes that
contained aberrant epigenetic patterns associated with the hiPSC
state. This analysis led us to identify a reprogramming-associated
epigenetic signature based on the methylation level of nine genes
that could segregate hESC and hiPSC lines in both the plurip-
otent state and after differentiation. There have been many
reports suggesting the existence of epigenetic and transcriptional
differences between hiPSC and hESC lines (11–24). Interestingly,
recently reported analysis using restricted representation bisulfite
sequencing (RRBS) showed that although cell line-specific out-
liers at both the methylation and gene expression levels could be
identified, no apparent epigenetic deviation was unique to all
hiPSC lines (23). However, the data presented therein (23) did
not appear to target any of the aberrantly methylated CpG sites
covered in our hiPSC-specific signature, because RRBS mainly
focuses on the analysis of CpG islands (resulting in low coverage
of genomic regions with low CpG density, including many func-
tional elements such as enhancers). When we compared the lists
of CpG sites associated with the nine genes characterized by our
dataset to the Bock et al. dataset (23), there was almost no overlap
between the two sets of analyzed CpG sites. In fact, in the Bock
et al. dataset (23), only 1 CpG site of the ∼600 we identified as
aberrantly methylated CpG sites associated to the 9 genes was
included in their analysis. Thus, when we clustered the pluripo-
tent cell lines used in the Lister et al. dataset (which analyzed
a near-complete selection of CpG sites genome-wide in an un-
biased manner; ref. 11) based on the CpG sites that were ana-
lyzed by the Bock et al. dataset, no clear separation was observed
Fig. 3. Reprogramming-associated epigenetic/tran-
scriptional signatures segregate hiPSCs and hESCs
after differentiation. (A) Percentage of aberrant CpG
sites identified between hESC-derived lines and
the corresponding hiPSC-derived lines classified
in the following categories: aberrant methylation
remains and is still aberrant compared with dif-
ferentiated hESCs (A); aberrant methylation remains
but is the same as the one found in differentiated
hESCs (B); aberrant methylation is removed during
differentiation reaching the level found in differ-
entiated hESCs (C); and aberrant methylation
changed to a new aberrant methylation state (D).
(B) Genes with aberrantly methylated CpG sites and
differential transcriptional abundance with at least
a twofold cutoff were identified in the HUVhiPS4F1
cell line after comparison with H9 cells. Graph shows
the relative fold change in the expression of genes
still aberrantly methylated after differentiation be-
tween the differentiated HUVhiPS4F1 cell line and
the differentiated hESC cell line. Note that differ-
ential expression was independent on whether
Activin or BMP4-differentiated cells were analyzed.
(C) Hierarchical clustering of hESC (H1, H9, HUES3,
HUES6, and HUES9) and hiPSC (HUVhiPS4F1, HUV-
hiPS4F3, HUVhiPS4F6, ASThiPS4F4, and ASThiPS4F5)
lines in their pluripotent and differentiated states
based on the methylation level of the nine common
aberrantly methylated genes identified in the hiPSC
lines used in this study. (D) Hierarchical clustering of
hESC (H9) and hiPSC (HUVhiPS4F1 and HUVhiPS4F3)
lines in their pluripotent and differentiated states
based on the gene expression level of the nine com-
mon aberrantly methylated genes identified in the
hiPSC lines used in this study. Data were obtained
from microarray analysis.
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between hESC and hiPSC lines. However, when we clustered the
hESC and hiPSC lines included in the Lister et al. dataset based
on the CpG sites analyzed in our study, we found that we were
able to segregate the two different pluripotent cell types. Fur-
thermore, when we compared our data to an extensive set of
genome-wide DNA methylation profiling of hESC and hiPSC
lines, that had analyzed CpG sites that overlapped with our
dataset (13), we were again able to separate these pluripotent cell
lines based on our identified hiPSC-specific epigenetic signature.
Altogether, these findings indicate that when characterizing the
epigenetic differences between hiPSCs and hESCs, cautions
must be taken to interpret the results when only a subset of ge-
nomic regions is investigated.
Furthermore, we also validated our reprogramming-associated
epigenetic signature by using gene expression data from several
previously reported datasets (refs. 13 and 32 and Dataset S2). We
observed that a majority of independent clusters separated hiPSC
and hESC lines, although clear outliers and different subgroups
among hiPSC lines were detected. This result is not totally un-
expected because it has been shown that gene expression levels in
pluripotent cells are highly variable and depend on how pluripotent
cells are generated or maintained (33). Moreover, Bock et al. (23)
also reported the existence of genes in pluripotent cells that con-
tained similar methylation levels but were associated to variable
levels of gene expression. Therefore, we cannot exclude the possi-
bility that some hiPSC lines might not segregate well from hESC
lines when using the gene expression levels of these nine genes to
cluster them.
Finally, although the genes TMEM132D, FAM19A5, and
TCERG1L have been reported to be involved in neural pro-
cesses, we did not identify any significant functional enrichment
associated with the nine genes aberrantly methylated in hiPSC
lines. Interestingly, Lister et al. (11) identified five of our nine genes
(TMEM132C, TMEM132D, FAM19A5, DPP6, and TCERG1L)
located within non-CG mega-DMRs as clear outliers in terms of
gene expression compared with hESCs. In fact, up to half of their
gene outliers located within non-CG mega-DMRs (11) were
observed aberrantly methylated in 14 of the 17 hiPSC used in this
study (Dataset S3). Further studies will be needed to better clarify
the role of non-CG mega-DMRs and their implication in the
functional behavior of hiPSCs compared with hESCs.
Overall, the results shown here demonstrate the existence of
intrinsic common reprogramming-associated epigenetic differences
associated with the hiPSC state. We demonstrated that the epige-
netic signature described in this work, based on the methylation
level of nine genes, can segregate hiPSC and hESC lines in both the
pluripotent state and after differentiation and could explain some of
the functional differences between these two pluripotent cell types.
Materials and Methods
Cell Culture.HumanH9 (WA09),H1 (WA01),HUES2,HUES3,HUES6,HUES8,and
HUES9 embryonic stem cell lineswere obtained fromWiCell Research Institute
or Harvard University and maintained as described (34). Derived hiPSCs were
cultured as described (34). IMR90 humanfibroblasts (ATCC; CCL-186) and 293T
cells were cultured in DMEM (Invitrogen) supplementedwith 10% FBS and 0.1
mM nonessential amino acids. HUVEC cells were obtained from Lonza (C-
2519A) and grown with EGM-2 media (Lonza) as recommended. MSCs were
kindly provided by Cécile Volle (Sanofi-Aventis, Toulouse, France) and grown in
α-MEM (Invitrogen) containing 10% FBS (HyClone), penicillin/streptomycin, so-
dium pyruvate, nonessential amino acids, and L-glutamine (all from Invi-
trogen). Human keratinocytes were obtained and cultured as described (35).
Additional experimental and data analysis procedures are provided in
SI Materials and Methods.
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